Last reviewed · How we verify
Tobramycin Inhalant Product
Tobramycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, leading to bactericidal activity against aerobic gram-negative and some gram-positive bacteria.
Tobramycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, leading to bactericidal activity against aerobic gram-negative and some gram-positive bacteria. Used for Chronic Pseudomonas aeruginosa airway infection in cystic fibrosis patients, Chronic suppressive therapy for gram-negative bacterial airway infections in cystic fibrosis.
At a glance
| Generic name | Tobramycin Inhalant Product |
|---|---|
| Also known as | Inhaled antibiotics |
| Sponsor | Shanghai Pulmonary Hospital, Shanghai, China |
| Drug class | Aminoglycoside antibiotic |
| Target | Bacterial 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Tobramycin inhalant products deliver the antibiotic directly to the lungs via aerosol, achieving high local concentrations in respiratory secretions. This formulation is particularly effective for treating chronic airway infections in cystic fibrosis patients, where it targets Pseudomonas aeruginosa and other susceptible pathogens that colonize the lungs. The inhalation route minimizes systemic exposure while maximizing therapeutic drug concentration at the site of infection.
Approved indications
- Chronic Pseudomonas aeruginosa airway infection in cystic fibrosis patients
- Chronic suppressive therapy for gram-negative bacterial airway infections in cystic fibrosis
Common side effects
- Cough
- Bronchospasm
- Wheezing
- Dysphonia
- Tinnitus
Key clinical trials
- Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis (PHASE4)
- Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis (PHASE3)
- Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tobramycin Inhalant Product CI brief — competitive landscape report
- Tobramycin Inhalant Product updates RSS · CI watch RSS
- Shanghai Pulmonary Hospital, Shanghai, China portfolio CI